A combination of Keytruda (pembrolizumab) and Lenvima (lenvatinib) worked better than standard Sutent (sunitinib) in improving survival outcomes among adults with untreated advanced renal cell carcinoma (RCC) — the most common type of kidney cancer in adults — according to top-line data from a Phase 3 clinical trial. A different Lenvima combination, with Novartis’ Afinitor (everolimus), also outperformed Sutent as a first-line therapy for this patient population, according to Lenvima’s developer, Eisai. Of note, Afinitor already…
You must be logged in to read/download the full post.
The post Keytruda-Lenvima Combo in Kidney Cancer Better Than Sutent in Improving Survival appeared first on BioNewsFeeds.